Clinical data | |
---|---|
Trade names | Ocaliva |
Other names | 6α-ethyl-chenodeoxycholic acid; INT-747 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a616033 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.238.318 |
Chemical and physical data | |
Formula | C26H44O4 |
Molar mass | 420.634 g·mol−1 |
3D model (JSmol) | |
Melting point | 108–110 °C (226–230 °F) [4] |
| |
|
Obeticholic acid (OCA), sold under the brand name Ocaliva, is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid. It is used as a medication used to treat primary biliary cholangitis. Intercept Pharmaceuticals Inc. hold the worldwide rights to develop OCA outside Japan and China, where it is licensed to Dainippon Sumitomo Pharma.[5]
{{cite journal}}
: CS1 maint: overridden setting (link)